

Synthesis of vitamin D₃ derivatives with nitrogen-linked substituents at A-ring C-2 and evaluation of their vitamin D receptor-mediated transcriptional activity†

Junko Abe,^a Yu Nagai,^a Rui Higashikuni,^a Keisuke Iida,^a Takatsugu Hirokawa,^b Hazuki Nagai,^c Kaichiro Kominato,^c Toshio Tsuchida,^c Michiko Hirata,^a Masaki Inada,^a Chisato Miyaoura^a and Kazuo Nagasawa^{*a}

Received 24th May 2012, Accepted 3rd August 2012

DOI: 10.1039/c2ob26017d

Binding of a series of novel 1 α ,25-dihydroxyvitamin D₃ (1,25-VD₃) derivatives, having a nitrogen-linked substituent at the 2 α - or 2 β -position of the A-ring (2-*N*-substituted compounds), with the vitamin D receptor (VDR) was investigated by means of computational docking studies. Selected compounds were synthesized by coupling A-ring synthons **6** and/or **7** with CD-ring-bearing bromomethylene **5** under Trost's conditions. The 2 α - and 2 β -stereoisomers of the A-ring synthons were synthesized from L-serine (**8**) as a single chiral source by installing vinyl and propargyl groups at opposite ends of the molecule. The activity of the obtained compounds was evaluated by means of a luciferase-based VDR transcriptional activity assay in NIH3T3 cells. Relatively small substituents incorporating a hydrogen-bonding donor, *i.e.*, NHAc and NHMs, were effective for eliciting VDR transcriptional activity, and 2 β -NHMs-1,25-VD₃ (**Xa**) showed the highest activity, being more potent than 1,25-VD₃. Derivatives with bulky substituents were inactive. These new insights into the structure–activity relationships of 1,25-VD₃ derivatives may be helpful in separating the various biological activities of 1,25-VD₃ and in generating novel therapeutic drug candidates.

1. Introduction

1 α ,25-Dihydroxyvitamin D₃ (**1**) (1,25-VD₃) (Fig. 1), the active metabolite of vitamin D₃, plays central roles in various biological processes, acting *via* its specific receptor, *i.e.*, vitamin D receptor (VDR), which is a member of the nuclear receptor (NR) superfamily.¹ 1,25-VD₃ modulates bone metabolism,² cell proliferation and cell differentiation.³ These characteristic biological activities deeply relate with various diseases, including osteoporosis, cancer, secondary hyperparathyroidism and psoriasis.⁴ Since 1,25-VD₃ and related compounds are promising candidates for the treatment of these diseases, thousands of vitamin D derivatives have been synthesized in attempts to separate and/or

enhance their biological activities,⁵ and some of these compounds are in clinical use.^{5a–c,e} In recent structure–activity relationship studies of vitamin D, much attention has been paid to modification of the A-ring.^{5b,c,e,6} This ring contains the 1 α - and 3 β -hydroxyl groups, which have important interactions with VDR at Ser237 and Arg274 (for the 1 α -hydroxyl group) and at Ser278 and Tyr143 (for the 3 β -hydroxyl group), as determined by X-ray analysis.¹⁰ The X-ray structure also indicated the presence of an unoccupied region in the binding site of VDR near the location of C2 of the A-ring of 1,25-VD₃. Therefore, introduction of substituents at C2 in the A-ring may alter the strength or the mode of interaction of the ligand with VDR, which may lead to conformational change of VDR, as well as changes in the characteristic biological activities. In fact, modification at the C2 position with oxygen- or carbon-containing groups has been intensively explored, and the resulting derivatives were reported to show characteristic and/or new biological activities.^{7–9} For example, introduction of a 2 α -hydroxypropyl⁸ or 2 α -methyl⁹ group increased the binding affinity for VDR by 4- and 3-fold, respectively. These analogs also showed extremely high calcium-mobilizing activity, having 7 and 500 times higher potency than 1,25-VD₃ (**1**), respectively.⁷ Further, introduction of a 2 β -hydroxypropoxy group afforded a compound (ED-71; **2**) that appears to increase the bone mineral density in osteoporotic patients

^aDepartment of Biotechnology and Life Science, Faculty of Technology, Tokyo University of Agriculture and Technology, 2-24-16 Naka-cho, Koganei, Tokyo 184-8588, Japan. E-mail: knaga@cc.tuat.ac.jp; Fax: +81-42-388-7295; Tel: +81-42-388-7295

^bNational Institute of Advanced Industrial Science and Technology Tokyo Waterfront Bio-IT Research Building, 2-4-7 Aomi, Koto-ku, Tokyo, 135-0064, Japan

^cMicroBiopharm Japan Co. 3-3-6 Nihonbashihoncho, Chuo-ku, Tokyo, 103-0032, Japan

†Electronic supplementary information (ESI) available. See DOI: 10.1039/c2ob26017d




Fig. 1 Structures of 1α,25-dihydroxyvitamin D₃ and its synthetic analogs modified at the C2 position.

without significant side effects.¹¹ An analog of 2MD (**4**) having a methylene group at C2 also caused a bone mass increment without inducing hypercalcemia.¹² These results clearly show the potential of modifications at the C2 position in the A-ring of the vitamin D skeleton for eliciting a broad range of biological activities.

Here, we focused on installing nitrogen-linked functional groups at C2 in the A-ring to obtain 2-*N*-substituted compounds. Nitrogen has a different electrostatic field from oxygen or carbon, as well as a different number of substituents and different bond angles. Therefore, vitamin D derivatives with *N*-substituents at the C2 position can be expected to show different VDR-binding modes from the corresponding oxygen and/or carbon-substituted vitamin D derivatives, and so might have characteristically different biological activities.¹³

Firstly, we carried out docking studies of various 2-*N*-substituted vitamin D derivatives, **I** ~ **X** (Fig. 2), with the AF2 domain of VDR using the Glide (Schrödinger, LLC).^{14,15} The docking scores are summarized in Table 1.¹⁶

In the case of 2α-*N*-monoalkyl groups (category **I**, **Ia–Ie**), higher stabilization was seen as the bulkiness increased from methyl to *n*-butyl group, but a remarkably low stabilization score was obtained for the *N*-benzyl-substituted derivative (**Ie**), probably because of steric hindrance. A similar trend was observed in the case of 2α-*N,N'*-dialkyl substitution (category **II**). The 2α-*N,N'*-diethyl-substituted derivative (**IIb**) was well docked with the AF2 domain (see Fig. 3(a)). Among the compounds in category **II**, no poses were obtained for the bulky *N,N'*-di-*n*-butyl- and *N,N'*-dibenzyl-substituted compounds (**IId** and **IIe**). Substitution of a 2α-*N*-amide group (category **III**) resulted in relatively low

calculated affinity for VDR. The docking result for the 2α-*N*-benzoyl derivative (**IIIc**) is illustrated in Fig. 3(b). The sterically hindered phenyl group in **IIIc** reduces the stability as a result of steric interaction with Lys240 of VDR. Moderate stabilization scores were obtained for carbamate-substituted derivatives (category **IV**). The 2α-*N*-acyl and carbamate groups showed no significant interaction of their carbonyl groups with amino acid residues of VDR. In the case of 2α-*N*-sulfonamide substitution (category **V**), no poses were obtained except for the *N*-methanesulfonamide derivative **Va**. This compound **Va** was well docked with VDR (see Fig. 3(c)), and it showed greater stabilization than 1,25-VD₃.

The 2β-*N*-substituted derivatives (categories **VI–X**) showed similar trends to the case of 2α-*N*-substitution. 2β-*N*-monoalkyl groups (**VIa–d**), a 2β-*N*-acetyl group (**VIIa**) and especially a *N*-methanesulfonyl group (**Xa**) were effective for stabilization of VDR. From the docking model (Fig. 3(d)), it appears that a hydrogen-bonding interaction between the sulfonyl group in **Xa** and Arg274 contributes to the stabilization.

Based upon these docking calculations, we selected **IId**, **IIe**, **IIIa–c**, **IVd**, **Va–d**, **VIIe**, **VIIIa**, and **Xa** as synthetic targets.

2. Synthesis of 2-*N*-substituted vitamin D derivatives

Palladium-catalyzed coupling reaction of vinyl bromide **5** (CD-ring) with an ene-yne-type A-ring synthon was developed by Trost for the synthesis of 2-*N*-substituted vitamin D derivatives.¹⁷ We planned to synthesize A-ring precursors of 2α- and 2β-*N*-substituted ene-yne **6** and **7** from L-serine (**8**) as a single chiral source by switching the positions of the vinyl and propargyl groups, as depicted in Scheme 1.

A-ring synthons for 2α-*N*-substituted-1,25-VD₃ derivatives **14–24** were synthesized from the key amine intermediate **13** (Scheme 2). Optically active allyl alcohol **9** was obtained from L-serine (**8**) according to Katsumura's method.¹⁸ The hydroxyl group of **9** was protected with TBS ether to give bis-TBS ether **10** in 93% yield. The primary TBS group in **10** was selectively deprotected with 1% HCl in ethanol to give alcohol **11**. In this reaction, the diol was co-generated in 23% yield, with 16% recovery of the starting bis-TBS ether **10**. The diol was quantitatively transformed back to the starting bis-TBS ether **10** with TBSOTf and 2,6-lutidine. Oxidation of the hydroxyl group under Swern conditions followed by reaction with propargyl Grignard reagent gave the alcohol as a 1 : 1 mixture of diastereomers,¹⁹ which were separated by column chromatography on silica gel to give **12** in 53% yield from **11**. The TBS ether and Boc group in **12** were deprotected with TFA, and resulting diol was protected as TBS ether with TBSOTf and 2,6-lutidine to afford the key amine intermediate **13** in 75% yield. *N,N'*-Dialkyl A-ring synthons **14–16** were synthesized in 51–60% yields by reductive amination with the corresponding aldehydes. In the case of NBN₂-substituted **16**, *N*-alkylation of amine **13** with benzyl bromide in the presence of potassium carbonate was more effective than a reductive amination protocol. *N*-Acyl derivatives **17–19** were synthesized by reaction with acyl halide or acyl anhydride in 90–96% yields. *N*-Sulfonamide derivatives **20–23** were synthesized by reaction of sulfonyl chloride in the

[illegible]

Other A-ring synthons with 2 β stereochemistry **32–34** were also synthesized from L-serine (**8**) (Scheme 3). Optically active Weinreb amide **25**,²⁰ derived from L-serine (**8**), was reacted with




Fig. 3 Selected docking models of 2-*N*-substituted 1,25-VD₃ with the AF2 domain of VDR calculated with Autodock.


vinyl magnesium bromide to give vinyl ketone **26** in 85% yield. Reduction of the ketone with zinc borohydride proceeded stereoselectively, affording the alcohol as a single stereoisomer,²¹ whose hydroxyl group was protected as TBS ether to give **27** in 89% yield in 2 steps. Ozonolysis of the vinyl group of **27** followed by reduction of the resulting ozonide with sodium borohydride gave the alcohol, which was treated with methanesulfonyl chloride followed by TBAF to give epoxide **28** in 76% yield in 3 steps.²² Opening reaction of the epoxide was carried out with trimethylsilyl acetylide in the presence of BF₃·Et₂O, and the resulting hydroxyl group was protected with *tert*-butyldiphenyl chloride (TBDPSCl) to give TBDPS ether **29** in 87% yield. The acetonide in **29** was deprotected with bismuth tribromide,²⁴ and the alcohol was oxidized with TPAP to give the aldehyde, which was subsequently reacted with vinylmagnesium bromide to give alcohol **30** as a mixture of two diastereomers (dr = 1 : 1) in 59% yield in 3 steps. After separation of the diastereomers on a silica gel column, deprotection of the TBDPS and TMS groups and the Boc group was conducted with TBAF and TFA, respectively, to give the diol, whose hydroxyl groups were protected as TBS ethers to give amine **31** in 61% yield. This key intermediate was converted into

N,N'-dibenzyl **32**, *N*-acetyl **33** and *N*-methanesulfonyl **34** by following the same procedures described for the synthesis of the corresponding 2α-stereoisomers of A-ring synthons **16**, **17**, and **20**.

With the *N*-substituted A-ring synthons with 2α and 2β stereochemistry, **14–24** and **32–34**, in hand, these A-ring precursors were coupled with the CD-ring bromomethylene **5** in the presence of Pd(PPh₃)₄,¹⁷ and the resulting TBS-protected coupling products were deprotected with TBAF or HF·Et₃N (Scheme 4) to afford the 2α-*N*-substituted vitamin D₃ derivatives **II–V**. 2β-*N*-Substituted 1,25-VD₃ derivatives **VIIe**, **VIIIa** and **Xa** were also obtained in 33, 17 and 21% yields, respectively.²⁵

3. Evaluation of VDR-mediated transcription-activating activity of 2-*N*-substituted 1,25-VD₃ derivatives


The biological activities of these 2-*N*-substituted 1,25-VD₃ derivatives were evaluated by means of a luciferase-based VDR transcriptional activity assay in NIH3T3 cells.²⁶ NIH3T3 cells



Scheme 1 Synthetic plan for A-ring synthons **6** and **7** of 2-*N*-substituted vitamin D₃ derivatives.

were transfected with pDR3-Luc and pGL4.74 [hLuc/TK] normalizing vectors, then treated with 1,25-VD₃ or compounds (100 nM **IIb**, **IIe**, **IIIa**–**c**, **IVd**, **Va**–**d**, **VIIe**, **VIIIa**, and **Xa**), and the luciferase activity was measured. The relative intensities of the luciferase activity of compounds *versus* the control or 1,25-VD₃ are summarized in Fig. 4.


Among the compounds tested, 2 α -NHAc-1,25-VD₃ (**IIIa**) showed similar activity to 1,25-VD₃, while **IVd** and **Va**, bearing NHBoc and NHMs groups at 2 α , showed moderate activity. Among the 2 β stereoisomers, the 2 β -*N*-acetyl derivative (**VIIIa**), which effectively stabilized VDR in the docking studies, showed potent activity nearly equal to that of 1,25-VD₃. However, 2 β -NHMs-1,25-VD₃ (**Xa**), which appeared to exhibit a hydrogen-bonding interaction with Arg274 of VDR in the docking studies, showed the highest transcriptional activity among the derivatives synthesized, being slightly more potent than VD₃. These derivatives all have a hydrogen-bond-donating group at the C2 position, so hydrogen bonding seems to be important for VDR transcriptional activity. Indeed, 2 α -NEt₂-1,25-VD₃ (**IIb**), which cannot form a hydrogen bond, induced no transcriptional activity, although it could be well docked with VDR by calculation. Steric hindrance is also an important factor. Compounds **IIe** and **VIIe** bearing bulky *N,N'*-Bn₂ groups at the 2 α - and 2 β -position, respectively, gave no calculated docking poses with VDR, and also failed to induce transcriptional activity. On the other hand, NHSO₂Ar can act as a hydrogen bond donor, but it is a bulky group, and it induced only low transcriptional activity. Thus, it appears that 2-*N*-substituted 1,25-VD₃ derivatives with a relatively small substituent group that has hydrogen-bond donor capability are effective for eliciting VDR transcriptional activity.



Scheme 2 Synthesis of 2 α -*N*-substituted A-ring synthons **14**–**24**. (a) TBSCl, imidazole, DMAP, DMF, rt, 93%; (b) 1% HCl, EtOH, rt, 60% (diol was generated in 23% yield, with 16% recovery of starting bis-TBS ether **10**); (c) (COCl)₂, DMSO, *i*-Pr₂NEt, CH₂Cl₂, –78 °C to 0 °C; (d) propargyl magnesium bromide, THF, 0 °C; (e) Separation with silica gel column, 53% (C3 isomer 35%); (f) 20% TFA–CH₂Cl₂, 0 °C to rt; (g) TBSOTf, 2,6-lutidine, CH₂Cl₂, 0 °C to rt, 75% (2 steps); (h) acetaldehyde (6 eq), NaBH₃CN, then AcOH, CH₃CN, 0 °C to rt, 51%; (i) *n*-butylaldehyde (6 eq), NaBH₃CN, then AcOH, CH₃CN, 0 °C to rt, 59%; (j) BnBr, K₂CO₃, CH₃CN, 80 °C, 60%; (k) acetic anhydride, rt, 94%; (l) pivaloyl chloride, triethylamine, CH₂Cl₂, 0 °C to rt, 96%; (m) benzoic anhydride, triethylamine, THF, 0 °C to rt, 90%; (n) methane-sulfonyl chloride, triethylamine, CH₂Cl₂, 0 °C to rt, 95%; (o) benzene-sulfonyl chloride, triethylamine, CH₂Cl₂, rt, 83%; (p) 4-*t*-butyl-benzenesulfonyl chloride, triethylamine, THF, rt, 80%; (q) 4-methoxy-benzenesulfonyl chloride, triethylamine, THF, rt, 93%; (r) TBSOTf, 2,6-lutidine, CH₂Cl₂, 0 °C, 38%.

4. Conclusion

In summary, we carried out computational docking with VDR for a series of novel 2 α - and 2 β -*N*-substituted 1,25-VD₃ derivatives. Based on the results, 14 compounds were selected and synthesized. A-Ring synthons for both stereoisomers were synthesized from L-serine (**8**) as a single chiral source by installing vinyl and propargyl groups at opposite ends of the molecule.




Scheme 3 Synthesis of 2 β -substituted A-ring synthons **32–34**. (a) vinyl magnesium bromide, THF, 0 °C, 85%; (b) Zn(BH₄)₂, Et₂O, –30 °C; (c) TBSCl, imidazole, DMAP, DMF, rt, 89% (2 steps); (d) O₃, CH₂Cl₂, MeOH, –78 °C, then NaBH₄, –78 °C to rt; (e) MsCl, triethylamine, CH₂Cl₂, 0 °C, 94% (2 steps); (f) TBAF, THF, rt, 81%; (g) trimethylsilyl acetylene, *n*-BuLi, BF₃·Et₂O, THF, –78 °C, 90%; (h) TBDPSCl, imidazole, DMF, rt to 40 °C, 97%; (i) BiBr₃, CH₃CN–H₂O, rt, 91%; (j) TPAP, NMO, MS-4A, CH₂Cl₂, rt, 92%; (k) vinyl magnesium bromide, THF, 0 °C, then separation (α -isomer: 35%, β -isomer: 35%); (l) TBAF, THF, rt, 89%; (m) 20% TFA–CH₂Cl₂, 0 °C to rt; (n) TBSOTf, 2,6-lutidine, CH₂Cl₂, 0 °C to rt, 69% (2 steps); (o) BnBr, K₂CO₃, CH₃CN, NaI, 80 °C, 54%; (p) Ac₂O, rt, 99%; (q) MsCl, Et₃N, CH₂Cl₂, 0 °C to rt, 84%.

These A-rings were coupled with CD-ring bromomethylene **5** according to Trost's protocol to afford the target compounds. In a dual-luciferase reporter assay, **IIIa**, **VIIIa** and **Xa** showed similar activity to 1,25-VD₃. Our results indicate that 2-*N*-substituted 1,25-VD₃ derivatives with a relatively small substituent group that has the potential to form a hydrogen bond with the receptor are effective for eliciting VDR transcriptional activity. Further structural development studies and evaluation of various VDR-mediated biological activities of our compounds are in progress.

Experimental

General

Flash chromatography was performed on Silica gel 60 (spherical, particle size 40–100 μ m; Kanto). Optical rotations were measured on a JASCO P-2200 polarimeter. ¹H and ¹³C NMR



Scheme 4 Synthesis of 2 α -*N*-substituted 1,25-VD₃ derivatives; **IIb** (NEt₂), 20%; **IIc** (N-*n*Bu₂), 10%; **IId** (NBn₂), 10%; **IIIa** (NHAc), 9%; **IIIb** (NHCO-*t*Bu), 57%; **IIIc** (NHCOPh), 25%; **IVd** (NHBoc), 20%; **Va** (NHSO₂Me), 57%; **Vb** (NHSO₂Ph), 5%; **Vc** (NHSO₂-4-*t*BuPh), 8%; **Vd** (NHSO₂-4-OMe-Ph), 6%. Synthesis of 2 β -*N*-substituted 1,25-VD₃ derivatives; **VIIe** (NBn₂), 33%; **VIIIa** (NHAc), 17%; **Xa** (NHSO₂Me), 21%.




Fig. 4 Results of dual-luciferase reporter assay for 2-*N*-substituted 1,25-VD₃ derivatives. Data are expressed as the means \pm SEM.

spectra were recorded on JEOL JNM-ECA 500, JNM-ECX 400 or JMT-C 300. The spectra are referenced internally according to residual solvent signals of CDCl₃ (¹H NMR; δ = 7.26 ppm, ¹³C NMR; δ = 77.0 ppm). Data for ¹H NMR are recorded as follows: chemical shift (δ , ppm), multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad), integration, coupling constant (Hz). Data for ¹³C NMR are reported in terms of chemical shift (δ , ppm). Mass spectra were recorded on JEOL JMS-T100X spectrometer with ESI-MS mode using methanol as solvent.

Bis-TBS ether 10. To a solution of **9** (16.7 mmol) in DMF (50 mL) was added imidazole (2.7 g, 40.1 mmol), DMAP (204 mg, 1.67 mmol) and TBSCl (3 g, 20.0 mmol), and the mixture was stirred for 24 h at room temperature. To the reaction mixture was added H₂O and then it was extracted with ethyl

acetate. The organic layer was washed with H₂O and brine, and the extracts were dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 100 : 1) to give **10** (6.9 g, 15.5 mmol, 93%). $[\alpha]_D^{25} = +3.4$ (*c* 1.3, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 5.76–5.90 (m, 1H), 5.10–5.28 (m, 2H), 4.62 (d, *J* = 7.3 Hz, 1H), 4.27 (brs, 1H), 3.76 (m, 1H), 3.69–3.55 (m, 2H), 1.42 (s, 9H), 0.89 (s, 9H), 0.88 (s, 9H), 0.07–0.01 (m, 12H); ¹³C NMR (75 MHz, CDCl₃) δ 155.6, 138.3, 116.2, 79.0, 73.1, 61.3, 56.4, 28.4, 25.8, 18.2, 18.1, –5.3, –5.5; HRMS: calcd for C₂₂H₄₇NO₄Si₂Na, 468.2941; found, 468.2940.

Alcohol 11. A solution of **10** (3.2 g, 7.18 mmol) in HCl and ethanol (1 : 99, 240 mL) was stirred for 15 min at room temperature. To the reaction mixture was added saturated NaHCO₃, then it was concentrated *in vacuo*. The residue was extracted with ethyl acetate and the organic layer was washed with H₂O and brine, and dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 4 : 1) to give **11** (1.43 g, 4.31 mmol, 60%). $[\alpha]_D^{22} = -20.8$ (*c* 5.2, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 5.88–5.79 (m, 1H), 5.40–5.18 (m, 3H), 4.52 (s, 1H), 3.97 (d, *J* = 11.4 Hz, 1H), 3.60–3.45 (m, 2H), 1.43 (s, 9H), 0.91–0.86 (m, 9H), 0.08–0.02 (m, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 155.7, 137.5, 116.3, 79.5, 76.0, 61.9, 54.6, 28.3, 25.7, 25.6, 18.0, –3.6; HRMS: calcd for C₁₆H₃₃NO₄SiNa, 354.2077; found, 354.2060.

Alcohol 12. To a solution of (COCl)₂ (0.6 mL, 7.29 mmol) in dichloromethane (30 mL) was added DMSO (1 mL, 14.3 mmol) dropwise at –78 °C. The reaction mixture was stirred for 10 min at –78 °C, and to the mixture was added dropwise a solution of **11** (1.05 g, 3.17 mmol) in dichloromethane (20 mL). The reaction mixture was stirred for 1.5 h at –78 °C, and diisopropylethylamine (5 mL, 28.5 mmol) was added. The resulting mixture was warmed to room temperature for 30 min. To the reaction mixture was added 1 N HCl, and the mixture was extracted with dichloromethane. The extracts were washed with H₂O, dried over MgSO₄, filtered, and concentrated *in vacuo* to give aldehyde. To a prepared solution of propargyl magnesium bromide (1 M in THF, 17 mL, 17.1 mmol) was added aldehyde in THF (15 mL) at 0 °C, and the mixture was stirred for 40 min. The resulting mixture was quenched by 1 N HCl at 0 °C and extracted with ethyl acetate. The organic layer was washed with H₂O and brine, and the extracts were dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 13 : 1) to give **12** (148 mg, 0.296 mmol, 53% from **11**). $[\alpha]_D^{22} = -25.6$ (*c* 2.2, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 5.90–5.82 (m, 1H), 5.39–5.20 (m, 3H), 4.61–4.57 (m, 1H), 4.27 (t, *J* = 6.9 Hz, 1H), 3.61 (s, 1H), 3.58 (dd, *J* = 8.9, 2.0 Hz, 1H), 2.35 (ddd, *J* = 58.3, 16.5, 2.9 Hz, 2H), 2.01 (t, *J* = 2.9 Hz, 1H), 1.44 (s, 9H), 0.91 (s, 9H), 0.08 (s, 3H), 0.04 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 155.6, 137.2, 116.7, 80.5, 79.6, 76.6, 70.1, 68.3, 55.0, 28.4, 25.8, 23.6, 18.0, –4.8, –5.3; HRMS: calcd for C₁₉H₃₅NO₄SiNa, 392.2233; found, 392.2267.

Amine 13. A solution of **12** (298 mg, 0.81 mmol) in TFA and dichloromethane (1 : 4, 8 mL) was stirred at 0 °C for 5 min and room temperature for 1 h. The reaction mixture was concentrated

in vacuo to give diol. To a solution of the resulting diol in dichloromethane (8 mL) was added 2,6-lutidine (0.6 mL, 4.84 mmol) and TBSOTf (0.6 mL, 2.42 mmol), and the mixture was stirred at 0 °C for 40 min. To the reaction mixture was added saturated NaHCO₃, then it was extracted with ethyl acetate. The organic layer was washed with H₂O and brine, and dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 40 : 1) to give **13** (250 mg, 0.65 mmol, 75% from **12**). $[\alpha]_D^{24} = -3.6$ (*c* 0.2, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 5.83–5.74 (m, 1H), 5.26–5.17 (m, 2H), 4.10–4.04 (m, 1H), 3.95 (t, *J* = 7.4 Hz), 2.86 (dd, *J* = 6.9, 2.8 Hz, 1H), 2.65–2.32 (m, 2H), 1.99 (t, *J* = 2.7 Hz, 1H), 0.91–0.88 (m, 18H), 0.12–0.03 (m, 12H); ¹³C NMR (100 MHz, CDCl₃) δ 139.2, 117.8, 81.2, 76.4, 70.4, 70.2, 58.3, 25.9, 24.9, 18.1, –3.3, –4.0; HRMS: calcd for C₂₀H₄₂NO₂Si₂, 384.2754; found, 384.2725.

2 α -N-Ethylamine 14. To a solution of **13** (100 mg, 0.26 mmol) in acetonitrile (2.6 mL) was added acetaldehyde (88 μ L, 1.56 mmol) and NaBH₃CN (41 mg, 0.65 mmol) at room temperature, and the mixture was stirred for 50 min. To the reaction mixture was added acetic acid until the pH of the mixture reached 3. The resulting mixture was stirred for 1.5 h and quenched by saturated NaHCO₃. The reaction mixture was extracted with ethyl acetate. The organic layer was washed with brine, and the extracts were dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 100 : 1) to give **14** (58 mg, 0.13 mmol, 51%). $[\alpha]_D^{20} = +4.8$ (*c* 0.9, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 5.98–5.87 (m, 1H), 5.28–5.12 (m, 2H), 4.38 (t, *J* = 8.9 Hz, 1H), 4.28–4.22 (m, 1H), 2.88–2.74 (m, 4H), 2.65–2.57 (m, 2H), 2.28–2.20 (m, 1H), 1.95 (t, *J* = 2.8 Hz, 1H), 0.97 (t, *J* = 7.1 Hz, 6H), 0.9–0.86 (m, 18H), 0.13–0.02 (m, 12H); ¹³C NMR (100 MHz, CDCl₃) δ 141.9, 117.2, 82.4, 74.3, 72.3, 69.8, 67.0, 47.9, 26.0, 24.4, 18.1, 16.4, –2.4, –4.1, –4.6; HRMS: calcd for C₂₄H₅₀NO₂Si₂, 440.3380; found, 440.3353.

2 α -N-*n*-Butylamine 15. To a solution of **13** (100 mg, 0.26 mmol) in acetonitrile (2.6 mL) was added *n*-butylaldehyde (140 μ L, 1.56 mmol) and NaBH₃CN (41 mg, 0.65 mmol) at room temperature, and the mixture was stirred for 1 h. To the reaction mixture was added acetic acid until the pH of the mixture reached 3. The resulting mixture was stirred for 1 h and quenched by saturated NaHCO₃. The reaction mixture was extracted with ethyl acetate. The organic layer was washed with brine, and the extracts were dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 100 : 1) to give **15** (76 mg, 0.15 mmol, 59%). $[\alpha]_D^{21} = +1.6$ (*c* 0.6, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 6.03–5.88 (m, 1H), 5.30–5.12 (m, 2H), 4.40 (t, *J* = 8.6 Hz, 1H), 4.28–4.20 (m, 1H), 2.89–2.62 (m, 5H), 2.60–2.49 (m, 2H), 2.31–2.21 (m, 1H), 1.95 (t, *J* = 2.5 Hz, 1H), 1.42–1.30 (m, 4H), 1.29–1.14 (m, 4H), 0.84–0.92 (m, 24H), 0.15–0.02 (m, 12H); ¹³C NMR (75 MHz, CDCl₃) δ 141.9, 117.1, 82.5, 74.6, 72.5, 69.9, 67.6, 54.6, 33.3, 26.0, 24.6, 20.5, 18.1, –2.4, –4.1; HRMS: calcd for C₂₈H₅₈NO₂Si₂, 496.4006; found, 496.4010.

2 α -N,N'-Dibenzylamine 16. To a solution of **13** (100 mg, 0.26 mmol) in acetonitrile (3 mL) was added K₂CO₃ (360 mg,

2.61 mmol) and BnBr (0.13 mL, 2.61 mmol) at room temperature, and the mixture was stirred at 80 °C for 10 h. To the resulting mixture was added saturated NH_4Cl , and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, and the extracts were dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 100 : 1) to give **16** (89 mg, 0.16 mmol, 60%). $[\alpha]_{\text{D}}^{24} = -14.4$ (c 3.9, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 7.40–7.16 (m, 10H), 6.08–5.97 (m, 1H), 5.44–5.27 (m, 2H), 4.54 (t, $J = 8.7$ Hz, 1H), 4.35–4.29 (m, 1H), 3.96 (dd, $J = 134.7, 13.8$ Hz, 4H), 2.91 (dd, $J = 8.5, 2.6$ Hz, 1H), 2.67–2.58 (m, 1H), 2.39–2.31 (m, 1H), 1.68 (t, $J = 2.5$ Hz, 1H), 0.89 (s, 9H), 0.82 (s, 9H), 0.13–0.03 (m, 12H); ^{13}C NMR (100 MHz, CDCl_3) δ 142.0, 140.9, 129.4, 127.9, 126.5, 117.6, 81.6, 75.1, 72.8, 69.8, 63.8, 56.5, 25.9, 18.1, –2.5, –4.0, –4.5; HRMS: calcd for $\text{C}_{34}\text{H}_{54}\text{NO}_2\text{Si}_2$, 564.3693; found, 564.3682.

2 α -N-Acetylamine 17. A solution of **13** (66 mg, 0.17 mmol) in acetic anhydride (0.5 mL) was stirred for 15 min at room temperature. The resulting mixture was concentrated *in vacuo* to give **17** (69 mg, 0.16 mmol, 94%). $[\alpha]_{\text{D}}^{25} = -12.8$ (c 0.4, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 5.91–5.82 (m, 1H), 5.69 (d, $J = 9.7$ Hz, 1H), 5.15–5.03 (m, 2H), 4.32–4.27 (m, 1H), 4.11 (t, $J = 9.2$ Hz, 1H), 3.96 (t, $J = 8.6$ Hz, 1H), 2.40–2.26 (m, 2H), 2.02 (t, $J = 2.6$ Hz, 1H), 1.94 (s, 3H), 0.92 (s, 9H), 0.88 (s, 9H), 0.14 (d, $J = 4.0$ Hz, 6H), 0.05 (s, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 169.8, 139.4, 117.4, 75.9, 70.9, 68.7, 55.8, 25.9, 25.4, 23.6, 18.1, –2.9, –4.0, –4.6; HRMS: calcd for $\text{C}_{22}\text{H}_{43}\text{NO}_3\text{Si}_2\text{Na}$, 448.2679; found 448.2674.

2 α -N-Pivaloylamine 18. To a solution of **13** (60 mg, 0.16 mmol) in dichloromethane (1.6 mL) was added Et_3N (33 μL , 0.23 mmol) and pivaloyl chloride (23 μL , 0.19 mmol) at room temperature, and the mixture was stirred for 4 h. To the reaction mixture was added saturated NH_4Cl , and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, and the extracts were dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 20 : 1) to give **18** (71 mg, 0.15 mmol, 96%). $[\alpha]_{\text{D}}^{27} = -1.6$ (c 1.1, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 6.03 (d, $J = 9.1$ Hz, 1H), 5.91–5.80 (m, 1H), 5.11–5.01 (m, 2H), 4.34–4.29 (m, 1H), 4.06 (t, $J = 9.2$ Hz, 1H), 3.93 (t, $J = 8.7$ Hz, 1H), 2.31–2.24 (m, 2H), 2.00 (t, $J = 2.8$ Hz, 1H), 1.14 (s, 9H), 0.92 (s, 9H), 0.88 (s, 9H), 0.14 (s, 6H), 0.05 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 177.7, 139.5, 117.2, 80.4, 76.2, 70.9, 69.1, 55.1, 38.7, 27.6, 25.9, 25.4, 18.0, –2.9, –4.0, –4.5, –4.6; HRMS: calcd for $\text{C}_{25}\text{H}_{49}\text{NO}_3\text{Si}_2\text{Na}$, 490.3149; found, 490.3123.

2 α -N-Benzoylamine 19. To a solution of **13** (120 mg, 0.31 mmol) in THF (3 mL) was added triethylamine (90 μL , 0.63 mmol) and benzoic anhydride (106 mg, 0.47 mmol) at room temperature, and the mixture was stirred for 15 min. To the resulting mixture was added saturated NH_4Cl , and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, and the extracts were dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 20 : 1) to give **19** (136 mg, 0.28 mmol, 90%). $[\alpha]_{\text{D}}^{25} = -17.2$ (c 1.2, CHCl_3);

^1H NMR (400 MHz, CDCl_3) δ 7.74–7.68 (m, 2H), 7.50–7.38 (m, 3H), 6.54 (d, $J = 9.7$ Hz, 1H), 6.01–5.91 (m, 1H), 5.14–5.06 (m, 2H), 4.42–4.38 (m, 1H), 4.34 (t, $J = 9.2$ Hz, 1H), 4.09 (t, $J = 8.7$ Hz, 1H), 2.47–2.30 (m, 2H), 2.00 (t, $J = 2.7$ Hz, 1H), 0.95 (s, 9H), 0.90 (s, 9H), 0.17 (d, $J = 5.5$ Hz, 6H), 0.68 (d, $J = 1.8$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.9, 139.3, 135.0, 131.3, 128.6, 126.7, 117.7, 80.2, 76.1, 71.0, 69.1, 56.1, 25.9, 25.6, 18.1, –2.9, –4.0, –4.6; HRMS: calcd for $\text{C}_{27}\text{H}_{45}\text{NO}_3\text{Si}_2\text{Na}$, 510.2836; found, 510.2806.

2 α -N-Methanesulfonylamine 20. To a solution of **13** (60 mg, 0.16 mmol) in dichloromethane (2 mL) was added triethylamine (53 μL , 0.37 mmol) and methanesulfonyl chloride (15 μL , 0.19 mmol) at 0 °C, and the mixture was stirred for 40 min at room temperature. To the resulting mixture was added saturated NaHCO_3 , and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, and the extracts were dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 20 : 1) to give **20** (69 mg, 0.19 mmol, 95%). $[\alpha]_{\text{D}}^{26} = -5.0$ (c 0.9, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 5.94–5.84 (m, 1H), 5.32–5.23 (m, 2H), 4.65 (d, $J = 9.2$ Hz, 1H), 4.23–4.17 (m, 1H), 4.11 (t, $J = 6.9$ Hz, 1H), 3.77–3.70 (m, 1H), 3.03 (s, 3H), 2.58–2.48 (m, 1H), 2.41–2.33 (m, 1H), 2.07 (t, $J = 2.8$ Hz, 1H), 0.89 (d, $J = 1.8$ Hz, 18H), 0.13 (d, $J = 5.5$ Hz, 6H), 0.08 (d, $J = 5.0$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 138.5, 118.2, 79.9, 75.6, 71.5, 69.9, 60.5, 42.7, 25.8, 25.1, 18.2, 18.0, –3.5, –4.0, –4.6; HRMS: calcd for $\text{C}_{21}\text{H}_{43}\text{NO}_4\text{SSi}_2\text{Na}$, 484.2349; found, 484.2358.

2 α -N-Benzenesulfonylamine 21. To a solution of **13** (110 mg, 0.29 mmol) in dichloromethane (3 mL) was added triethylamine (0.1 mL, 0.69 mmol) and benzenesulfonyl chloride (45 μL , 0.34 mmol) at room temperature, and the mixture was stirred for 6 h. The reaction mixture was diluted with H_2O and extracted with ethyl acetate. The organic layer was washed with brine, and the extracts were dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 40 : 1) to give **21** (124 mg, 0.24 mmol, 83%). $[\alpha]_{\text{D}}^{18} = -26.5$ (c 0.9, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 7.91–7.85 (m, 2H), 7.59–7.44 (m, 3H), 5.74–5.62 (m, 1H), 5.13–4.85 (m, 2H), 4.15 (q, $J = 4.6$ Hz, 1H), 4.00 (t, $J = 7.8$ Hz, 1H), 3.58 (t, $J = 8.3$ Hz, 1H), 2.14–2.06 (m, 1H), 1.98 (t, $J = 2.5$ Hz, 1H), 1.93–1.83 (m, 1H), 0.86 (s, 18H), 0.07 (d, $J = 5.5$ Hz, 6H), 0.02 (d, $J = 3.7$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 141.8, 138.7, 132.4, 128.9, 127.0, 118.1, 80.2, 75.7, 71.1, 69.4, 59.9, 24.8, 18.1, 18.0, –3.3, –4.3, –4.5, –4.7; HRMS: calcd for $\text{C}_{26}\text{H}_{45}\text{NO}_4\text{SSi}_2\text{Na}$, 546.2506; found, 546.2500.

2 α -N-(4-*tert*-Butyl)-benzenesulfonylamine 22. To a solution of **13** (65 mg, 0.17 mmol) in THF (2 mL) was added triethylamine (57 μL , 0.41 mmol), 4-*tert*-butyl-benzenesulfonyl chloride (47 mg, 0.20 mmol) at room temperature, and the mixture was stirred for 8 h. The reaction mixture was warmed to 60 °C and stirred additional 8 h. The resulting mixture was diluted with H_2O at room temperature and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, and the extracts were dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography

(hexane–ethyl acetate = 30 : 1) to give **22** (78.9 mg, 0.14 mmol, 80%). $[\alpha]_{\text{D}}^{19} = -18.7$ (*c* 2.7, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 7.82–7.76 (m, 2H), 7.51–7.45 (m, 2H), 5.74–5.59 (m, 1H), 5.12–4.85 (m, 2H), 4.16–4.09 (m, 1H), 4.01 (t, *J* = 7.6 Hz, 1H), 3.58–3.48 (m, 1H), 2.16–1.92 (m, 3H), 1.33 (s, 9H), 0.86 (d, *J* = 1.4 Hz, 18H), 0.60 (s, 6H), 0.01 (d, *J* = 3.4 Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 156.2, 138.7, 126.9, 125.8, 117.8, 80.4, 75.6, 70.9, 69.6, 59.9, 35.1, 31.1, 25.8, 24.8, 18.1, 18.0, –3.3, –4.3, –4.5, –4.7; HRMS: calcd for $\text{C}_{30}\text{H}_{53}\text{NO}_4\text{SSi}_2\text{Na}$, 602.3132; found, 602.3137.

2 α -N-(4-Methoxy)-benzenesulfonylamine 23. To a solution of **13** (90 mg, 0.24 mmol) in THF (2 mL) was added triethylamine (79 μL , 0.56 mmol) and 4-methoxybenzenesulfonyl chloride (58 mg, 0.28 mmol) at room temperature, and the mixture was stirred for 3 h. To the reaction mixture was added saturated NH_4Cl , and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, and the extracts were dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 15 : 1) to give **23** (122 mg, 0.22 mmol, 93%). $[\alpha]_{\text{D}}^{18} = -27.2$ (*c* 2.3, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 7.80 (d, *J* = 9.0 Hz, 2H), 6.94 (d, *J* = 8.9 Hz, 2H), 5.77–5.62 (m, 1H), 5.14–5.03 (m, 2H), 4.84 (d, *J* = 8.9 Hz, 1H), 4.19–4.11 (m, 1H), 4.01 (t, *J* = 7.7 Hz, 1H), 3.86 (s, 3H), 3.58–3.49 (m, 1H), 2.18–1.89 (m, 3H), 0.86 (s, 18H), 0.07 (d, *J* = 2.4 Hz, 6H), 0.02 (d, *J* = 3.5 Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 162.6, 138.8, 133.6, 129.2, 118.0, 114.0, 80.4, 75.7, 71.0, 69.4, 59.8, 55.6, 25.9, 24.9, 18.1, 18.0, –3.3, –4.3, –4.5, –4.7; HRMS: calcd for $\text{C}_{27}\text{H}_{47}\text{NO}_5\text{SSi}_2\text{Na}$, 576.2611; found, 576.2606.

2 α -N-tert-Butoxycarbonylamine 24. To a solution of **12** (124 mg, 0.34 mmol) in dichloromethane (3 mL) was added 2,6-lutidine (78 μL , 0.67 mmol) and TBSOTf (85 μL , 0.37 mmol) at 0 °C, and the mixture was stirred for 50 min at room temperature. To the resulting mixture was added 2,6-lutidine (40 μL) and TBSOTf (50 μL) additionally at room temperature. The reaction mixture was diluted with H_2O , and extracted with ethyl acetate. The organic layer was washed with brine, and the extracts were dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 50 : 1) to give **24** (62.4 mg, 0.13 mmol, 38%). $[\alpha]_{\text{D}}^{24} = -20.7$ (*c* 0.8, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 5.95–5.83 (m, 1H), 5.15–5.08 (m, 2H), 4.69 (d, *J* = 10.1 Hz, 1H), 4.29–4.22 (m, 1H), 3.97 (t, *J* = 8.7 Hz, 1H), 3.78 (t, *J* = 9.2 Hz, 1H), 2.47–2.25 (m, 2H), 2.01 (t, *J* = 2.7 Hz, 1H), 1.41 (s, 9H), 0.91 (s, 9H), 0.88 (s, 9H), 0.12 (d, *J* = 4.6 Hz, 6H), 0.05 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 155.8, 139.4, 117.4, 80.6, 78.9, 76.0, 70.7, 69.2, 57.2, 28.4, 25.9, 25.2, 18.1, –2.9, –4.1, –4.5, –4.6; HRMS: calcd for $\text{C}_{25}\text{H}_{49}\text{NO}_4\text{Si}_2\text{Na}$, 506.3098; found, 506.3075.

Vinyl ketone 26. To a solution of **25** (5.80 g, 20.1 mmol) in THF (40 mL) was added vinylmagnesium bromide (1 M in THF, 25 mL, 25 mmol) at 0 °C, and the mixture was stirred for 2 h at room temperature. The resulting mixture was quenched by 1 N HCl at 0 °C and extracted with ethyl acetate. The organic layer was washed with brine, and the extracts were dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 10 : 1) to give

26 (4.37 g, 17.1 mmol, 85%). $[\alpha]_{\text{D}}^{20} = -33.0$ (*c* 0.7, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 6.56 (ddd, *J* = 10.3, 17.2, 17.2 Hz, 1H), 6.34 (dd, *J* = 4.4, 17.2 Hz, 1H), 5.85 (dd, *J* = 1.3, 10.3 Hz, 1H), 4.78–4.53 (m, 1H), 4.23–4.13 (m, 1H), 4.00–3.98 (m, 1H), 1.72–1.34 (m, 15H); ^{13}C NMR (100 MHz, CDCl_3) δ 196.7, 151.3, 131.8, 129.9, 95.2, 80.7, 65.6, 63.9, 28.3, 28.2; HRMS: (ESI, $\text{M} + \text{Na}^+$) calcd for $\text{C}_{13}\text{H}_{21}\text{NO}_4\text{Na}$, 278.1368; found, 278.1360.

TBS ether 27. To a solution of **26** (334.5 mg, 1.31 mmol) in diethyl ether (13 mL) was added a 0.18 M diethyl ether solution of $\text{Zn}(\text{BH}_4)_2$ (5 mL) at –20 °C, and the mixture was stirred for 1 h. To the resulting mixture was added 1 N HCl at 0 °C and the mixture was extracted with ethyl acetate. The extracts were washed with brine, and the organics were dried over MgSO_4 , filtered, and concentrated *in vacuo* to give alcohol (328.7 mg). To a solution of the resulting alcohol (328.7 mg) in DMF (2 mL) was added imidazole (215 mg, 3.16 mmol), TBSCl (238 mg, 1.58 mmol) and DMAP (16 mg, 0.132 mmol) at room temperature, and the mixture was stirred for 5 h. To the reaction mixture was added saturated NaHCO_3 , and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, and the extracts were dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 50 : 1) to give **27** (434.7 mg, 1.17 mmol, 89% from **26**). $[\alpha]_{\text{D}}^{21} = -34.9$ (*c* 1.2, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 5.84–5.67 (m, 1H), 5.28–5.04 (m, 2H), 4.59–4.21 (m, 1H), 4.03 (d, *J* = 5.1 Hz, 1H), 3.90–3.83 (m, 1H), 3.83–3.71 (m, 1H), 1.46 (s, 9H), 0.88 (s, 9H), 0.00 (s, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 152.7, 152.1, 139.2, 138.9, 116.2, 115.5, 94.2, 94.0, 79.9, 79.7, 74.3, 71.9, 64.3, 63.1, 61.6, 61.4, 28.4, 26.7, 25.9, 25.8, 25.2, 23.2, 18.0, –4.4, –4.6; HRMS: (ESI, $\text{M} + \text{Na}^+$) calcd for $\text{C}_{19}\text{H}_{37}\text{NO}_4\text{SiNa}$, 394.2389; found, 394.2387.

Epoxide 28. A solution of **27** (3.12 g, 8.4 mmol) in dichloromethane (40 mL) and methanol (40 mL) was treated with ozone at –78 °C with stirring for 40 min. Then NaBH_4 (1.9 g, 50.4 mmol) was added to the resulting mixture, which was warmed up slowly to room temperature over 12 h. To the reaction mixture was added 3 N HCl, and the organic layer was extracted with dichloromethane. The extracts were dried over MgSO_4 , filtered, and concentrated *in vacuo* to give alcohol (3.2 g). To a solution of the alcohol (3.2 g) in dichloromethane (30 mL) was added triethylamine (1.8 mL, 12.6 mmol) and methanesulfonyl chloride (1.3 mL, 16.8 mmol) at room temperature, and the mixture was stirred for 1.5 h. The resulting mixture was diluted with H_2O and extracted with dichloromethane, and the extracts were dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 10 : 1) to give mesylate (3.59 g, 7.91 mmol, 94% from **27**). To a solution of mesylate (175.3 mg, 0.386 mmol) in THF (5 mL) was added TBAF (505 mg, 1.93 mmol) at room temperature, and the mixture was stirred for 10 min. To the reaction mixture was added saturated NH_4Cl , and the organic layer was extracted with ethyl acetate. The extracts were washed with brine, dried over MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 20 : 1) to give **28** (75.8 mg,

0.311 mmol, 81%). $[\alpha]_D^{22} = +12.5$ (*c* 1.1, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 4.10–3.95 (m, 2H), 3.61–3.38 (m, 1H), 3.00 (s, 1H), 2.89 (s, 1H), 2.86–2.70 (m, 1H), 1.69–1.42 (m, 15H); ¹³C NMR (100 MHz, CDCl₃) δ 152.3, 151.7, 94.3, 93.7, 80.4, 80.0, 66.0, 65.4, 59.2, 58.9, 52.3, 51.9, 48.3, 48.2, 28.3, 28.2, 27.4, 26.6, 24.2, 23.0; HRMS: (ESI, M + Na⁺) calcd for C₁₂H₂₁NO₄Na, 266.1368; found, 266.1361.

Silyl ether 29. To a solution of trimethylsilylacetylene (1.6 mL, 11.3 mmol) in THF (45 mL) was added *n*-butyllithium (1.6 M in hexane, 6.8 mL, 11.3 mmol) at 0 °C, and the mixture was stirred for 10 min. To the reaction mixture was added a solution of **28** (1.83 g, 7.53 mmol) in THF (15 mL) and BF₃–Et₂O (1.9 mL, 15.0 mmol) at –78 °C. After being stirred for 1 h, triethylamine (10 mL, 75.2 mmol) was added to the resulting mixture. The reaction mixture was warmed to room temperature, and concentrated *in vacuo*. The residue was filtered through a pad of silica gel using ethyl acetate to give alcohol (2.32 g, 6.78 mmol, 90%). To a solution of alcohol (2.21 g, 6.47 mmol) in DMF (1 mL) was added imidazole (1.7 g, 25.9 mmol) and TBDPSCl (2.5 mL, 9.71 mmol) at room temperature, and the mixture was stirred at 40 °C for 8 h. To the reaction mixture was added saturated NaHCO₃, and the organic layer was extracted with ethyl acetate. The extracts were washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 100 : 1) to give **29** (3.63 g, 6.26 mmol, 97%). $[\alpha]_D^{17} = -61.0$ (*c* 1.7, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.75–7.67 (m, 4H), 7.45–7.34 (m, 6H), 4.46 (dd, *J* = 8.3, 2.1 Hz, 1H), 4.33–4.20 (m, 1H), 4.04–3.91 (m, 2H), 2.23–2.12 (m, 2H), 1.59–1.35 (m, 15H), 1.08 (s, 9H), 0.12 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 153.2, 152.4, 135.8, 135.7, 134.7, 134.2, 129.7, 129.6, 127.6, 127.5, 103.6, 103.1, 94.3, 93.6, 87.2, 79.9, 71.2, 70.7, 63.5, 62.3, 61.1, 28.4, 27.0, 26.4, 19.4, –0.06; HRMS: (ESI, M + Na⁺) calcd for C₃₃H₄₉NO₄Si₂Na, 602.3097; found, 602.3079.

Allyl alcohol 30. To a solution of **29** (3.63 g, 6.26 mmol) in acetonitrile (40 mL) was bismuth tribromide (281 mg, 0.626 mmol) at room temperature, and the mixture was stirred for 1 h. To the reaction mixture was added H₂O (0.1 mL) at room temperature and the mixture was stirred for 30 min. To the resulting mixture was added saturated NaHCO₃, and the organic layer was extracted with ethyl acetate. The extracts were washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 10 : 1) to give alcohol (3.09 g, 5.72 mmol, 91%). To a solution of the alcohol (322 mg, 0.596 mmol) in dichloromethane (6 mL) was added NMO (83 mg, 0.709 mmol) and MS 4Å (330 mg) at room temperature, then TPAP (23 mg, 0.0656 mmol) was added and the resulting mixture was stirred for 20 min. The reaction mixture was filtered through a pad of silica gel using ethyl acetate, and eluted fractions were concentrated *in vacuo* to give aldehyde (297.1 mg, 0.550 mmol, 92%). To a solution of the aldehyde (212.4 mg, 0.513 mmol) in THF (5 mL) was added vinylmagnesium bromide (1 M in THF, 1.5 mL, 1.5 mmol) at 0 °C, and the mixture was stirred for 30 min. To the reaction mixture was added 1 N HCl at 0 °C, and organic layer was extracted with

ethyl acetate. The extracts were washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 20 : 1) to give **30** (79.3 mg, 0.179 mmol, 35%). $[\alpha]_D^{25} = -12.8$ (*c* 1.2, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.70–7.68 (m, 4H), 7.49–7.38 (m, 6H), 5.78 (ddd, *J* = 16.6, 10.9, 5.4 Hz, 1H), 5.39–5.29 (m, 2H), 5.16 (d, *J* = 10.3 Hz, 1H), 4.81–4.78 (m, 1H), 4.12–4.09 (m, 1H), 3.76–3.74 (m, 1H), 2.41 (dd, *J* = 17.7, 6.3 Hz, 1H), 2.34 (dd, *J* = 17.7, 4.6 Hz, 1H), 1.40 (s, 9H), 1.10 (s, 9H), 0.13 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 155.9, 137.2, 135.8, 132.8, 132.1, 130.1, 127.8, 115.8, 102.3, 88.2, 79.2, 73.0, 70.9, 56.9, 28.3, 26.9, 25.5, 19.3, –0.12; HRMS: (ESI, M + Na⁺) calcd for C₃₂H₄₇NO₄Si₂Na, 588.2941; found, 588.2934.

Amine 31. To a solution of **30** (665.4 mg, 1.18 mmol) in THF (10 mL) was added TBAF (771 mg, 2.95 mmol) at room temperature, and the mixture was stirred for 40 min. To the reaction mixture was added saturated NH₄Cl, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, and the extracts were dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 2 : 1) to give diol (268.6 mg, 1.05 mmol, 89%). To the diol (268.6 mg, 1.05 mmol) was added a mixed solution of TFA and dichloromethane (1 : 4, 5 mL) at 0 °C, and the mixture was stirred for 2 h at room temperature. The reaction mixture was concentrated *in vacuo* to give diol (309.3 mg). To a solution of the diol (309.3 mg) in dichloromethane (3 mL) was added 2,6-lutidine (1.4 mL, 12.6 mmol) and TBSOTf (1.2 mL, 5.25 mmol) at 0 °C, and the mixture was stirred for 8 h at room temperature. To the reaction mixture was added saturated NaHCO₃, and extracted with ethyl acetate. The organic layer was washed with H₂O and brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 50 : 1) to give **31** (278.1 mg, 0.726 mmol, 69% from the diol). $[\alpha]_D^{19} = -1.9$ (*c* 1.0, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 5.87 (ddd, *J* = 17.4, 10.5, 7.3 Hz, 1H), 5.21 (d, *J* = 17.4 Hz, 1H), 5.16 (d, *J* = 10.5 Hz, 1H), 4.12 (dd, *J* = 5.9, 7.3 Hz, 1H), 3.82 (ddd, *J* = 4.4, 4.4, 6.7 Hz, 1H), 2.83 (dd, *J* = 4.58, 5.50 Hz, 1H), 2.53 (dd, *J* = 17.4, 6.87, 2.75 Hz, 1H), 2.44 (dd, *J* = 17.4, 4.58, 2.75 Hz, 1H), 1.93 (t, *J* = 2.75 Hz, 1H), 0.89 (s, 9H), 0.88 (s, 9H), 0.11 (s, 3H), 0.075 (s, 3H), 0.068 (s, 3H), 0.030 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 139.3, 116.5, 82.4, 75.0, 71.8, 69.8, 61.0, 25.9, 25.8, 22.5, 18.1, 18.0, –3.5, –3.7, –4.6, –4.7; HRMS: (ESI, M + H⁺) calcd for C₂₀H₄₂NO₂Si₂, 384.2754; found, 384.2745.

2 β -N,N'-Dibenzylamine 32. To a solution of **31** (30.4 mg, 0.0792 mmol) in acetonitrile (1 mL) was added K₂CO₃ (66 mg, 0.475 mmol) and BnBr (38 μ L, 0.317 mmol) at room temperature, and the mixture was stirred for 1 h at 80 °C. To the reaction mixture was added NaI (14 mg, 0.095 mmol) at room temperature, and the mixture was stirred at 80 °C for 21 h. To the reaction mixture was added saturated NH₄Cl at room temperature, and organic layer was extracted with ethyl acetate. The extracts were washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 100 : 1) to give **32** (24 mg,

0.0426 mmol, 54%). $[\alpha]_D^{26} = +6.8$ (c 0.2, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.38–7.14 (m, 10H), 6.08 (ddd, $J = 7.91, 10.3, 17.5$ Hz, 1H), 5.16 (d, $J = 17.2$ Hz, 1H), 4.99 (d, $J = 9.9$ Hz, 1H), 4.65 (dd, $J = 5.1, 7.9$ Hz, 1H), 4.28 (ddd, $J = 4.8, 5.1, 7.4$ Hz, 1H), 4.09 (d, $J = 14.1$ Hz, 2H), 3.84 (d, $J = 13.8, 2H$), 2.96 (dd, $J = 4.8, 5.1$ Hz, 1H), 2.76 (dd, $J = 2.7, 7.2, 16.8$ Hz, 1H), 2.34 (ddd, $J = 2.7, 5.1, 16.8$ Hz, 1H), 1.77 (t, $J = 2.7$ Hz, 1H), 0.90 (s, 9H), 0.87 (s, 9H), 0.085 (s, 3H), 0.060 (s, 3H), 0.044 (s, 3H), 0.040 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 141.9, 140.9, 129.1, 128.1, 126.6, 115.2, 76.4, 73.1, 70.8, 69.8, 64.7, 56.0, 53.5, 29.8, 26.3, 26.1, 18.3, –3.3, –3.4, –4.2, –4.4; HRMS: (ESI, M + H⁺) calcd for C₃₄H₅₄NO₂Si₂, 564.3693; found, 564.3648.

2 β -N-Acetylamine 33. A solution of **31** (127.6 mg, 0.333 mmol) in acetic anhydride (0.3 mL) was stirred for 20 min at room temperature. The reaction mixture was concentrated *in vacuo* to give **33** (140.1 mg, 0.329 mmol, 99%). $[\alpha]_D^{17} = +8.90$ (c 0.6, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 5.87 (d, $J = 9.6$ Hz, 1H), 5.80 (ddd, $J = 17.4, 10.1, 7.3$ Hz, 1H), 5.19 (d, $J = 17.4$ Hz, 1H), 5.11 (d, $J = 10.1$ Hz, 1H), 4.48 (d, $J = 7.3$ Hz, 1H), 3.97 (ddd, $J = 9.6, 7.8, 1.8$ Hz, 1H), 3.93–3.87 (m, 1H), 2.56 (ddd, $J = 16.9, 6.4, 2.8$ Hz, 1H), 2.36 (ddd, $J = 16.9, 5.0, 2.8$ Hz, 1H), 2.02 (t, $J = 2.7$ Hz, 1H), 2.00 (s, 3H), 0.91 (s, 9H), 0.90 (s, 9H), 0.14 (s, 3H), 0.12 (s, 3H), 0.098 (s, 3H), 0.056 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 169.9, 138.6, 116.2, 81.8, 72.4, 71.5, 70.3, 58.2, 24.8, 23.4, 18.1, 18.0, –4.4, –4.6; HRMS: (ESI, M + Na⁺) calcd for C₂₂H₄₃NO₃Si₂Na, 448.2679; found, 448.2667.

2 β -N-Methanesulfonylamine 34. To a solution of **31** (92.8 mg, 0.242 mmol) in dichloromethane (2 mL) was added triethylamine (81 μ L, 0.581 mmol) and methanesulfonyl chloride (22 μ L, 0.290 mmol) at room temperature, and the mixture was stirred for 15 min. The resulting mixture was quenched with saturated NH₄Cl and extracted with ethyl acetate. The organic layer was washed with brine, and the extracts were dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 30 : 1) to give **34** (94.2 mg, 0.204 mmol, 84%). $[\alpha]_D^{18} = +15.2$ (c 0.9, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 5.94 (ddd, $J = 7.2, 10.3, 17.2$ Hz, 1H), 5.25 (d, $J = 17.2$ Hz, 1H), 5.22 (d, $J = 10.3$ Hz, 1H), 4.85 (d, $J = 8.9$ Hz, 1H), 4.42 (dd, $J = 2.4, 7.2$ Hz, 1H), 3.91 (dd, $J = 5.16, 10.6$ Hz, 1H), 3.53 (ddd, $J = 2.7, 5.5, 8.6$ Hz, 1H), 3.08 (s, 3H), 2.59 (ddd, $J = 2.4, 5.1, 17.2$ Hz, 1H), 2.47 (ddd, $J = 2.7, 5.1, 17.2$ Hz, 1H), 2.08–2.02 (m, 1H), 0.91 (s, 9H), 0.89 (s, 9H), 0.15 (s, 3H), 0.12 (s, 3H), 0.088 (s, 3H), 0.059 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 138.3, 116.9, 81.1, 73.3, 71.3, 62.5, 42.3, 25.8, 25.7, 24.1, 18.0, –3.8, –4.1, –4.5, –4.7; HRMS: (ESI, M + Na⁺) calcd for C₂₁H₄₃NO₄SSi₂Na, 484.2349; found, 484.2368.

2 α -N,N'-Diethyl-1 α -25(OH)₂ vitamin D₃ (IIb). To a solution of **5** (37 mg, 0.09 mmol) and **14** (45 mg, 0.10 mmol) in toluene and triethylamine (1 : 1, 2 mL) was added Pd(PPh₃)₄ (about 50 mg) at room temperature. The resulting mixture was stirred at room temperature for 15 min and 90 °C for 2 h. The reaction mixture was cooled to room temperature, and diluted with ethyl acetate, filtered through a pad of Celite, and concentrated

in vacuo. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 50 : 1) to give bis silylether. To a solution of in THF (3 mL) was added TBAF (71 mg, 0.27 mmol) at room temperature, and the mixture was stirred at 60 °C for 3 h. To the reaction mixture was added saturated NH₄Cl at room temperature, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (CHCl₃–methanol = 5 : 1) to give **IIb** (8 mg, 0.02 mmol, 22%). $[\alpha]_D^{22} = +9.6$ (c 0.6, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 6.42 (d, $J = 11.5$ Hz, 1H), 5.94 (d, $J = 11.0$ Hz, 1H), 5.32 (s, 1H), 5.00 (s, 1H), 4.45–4.35 (m, 1H), 4.20–4.31 (m, 1H), 3.79–3.36 (m, 5H), 2.84–2.75 (m, 1H), 2.44 (t, $J = 11.9$ Hz, 1H), 2.25–0.70 (m, 37H), 0.50 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 143.8, 143.6, 130.6, 125.5, 117.3, 117.1, 71.5, 70.0, 69.0, 65.3, 56.5, 56.3, 47.8, 45.9, 44.6, 44.4, 40.5, 36.3, 36.1, 29.5, 29.2, 29.1, 27.6, 23.4, 22.1, 20.8, 18.8, 12.1; HRMS: calcd for C₃₁H₅₄NO₃, 488.4104; found, 488.4078.

2 α -N-Substituted vitamin D₃ derivatives II d–e, III a–c, IV d, Va–d. As described for **IIb**, **II d–e**, **III a–c**, **IV d** and **Va–d** were obtained from the corresponding A-ring synthons (**15–24**).

2 α -N,N'-Dibutyl-1 α -25(OH)₂ vitamin D₃ (II d). $[\alpha]_D^{23} = +20.7$ (c 0.5, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 6.49 (d, $J = 10.8$ Hz, 1H), 5.94 (d, $J = 10.9$ Hz, 1H), 5.30 (s, 1H), 5.02 (s, 1H), 4.63 (s, 1H), 4.15–4.29 (m, 1H), 3.35–2.72 (m, 9H), 2.40–2.25 (m, 1H), 2.20–0.70 (m, 42H), 0.51 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.1, 132.1, 130.9, 128.5, 126.1, 116.7, 72.5, 71.1, 68.4, 64.5, 56.5, 56.3, 51.0, 45.9, 44.4, 43.7, 40.5, 36.4, 36.1, 31.9, 29.7, 29.6, 29.4, 29.1, 27.6, 23.5, 22.7, 22.2, 20.9, 20.8, 18.8, 14.1, 14.0, 12.1; HRMS: calcd for C₃₅H₆₂NO₃, 544.4730; found, 544.4711.

2 α -N,N'-Dibenzyl-1 α -25(OH)₂ vitamin D₃ (II e). $[\alpha]_D^{31} = +18.3$ (c 0.5, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 7.38–7.18 (m, 10H), 6.47 (d, $J = 11.4$ Hz, 1H), 5.94 (d, $J = 11.4$ Hz, 1H), 5.21 (d, $J = 1.9$ Hz, 1H), 4.89 (d, $J = 1.8$ Hz, 1H), 4.66 (d, $J = 1.8$ Hz, 1H), 4.26–4.08 (m, 2H), 3.93 (dd, $J = 178.4, 13.7$ Hz, 4H), 2.82 (d, $J = 12.4$ Hz, 1H), 2.76 (dd, $J = 13.1, 5.3$ Hz, 1H), 2.60 (dd, $J = 10.1, 2.3$ Hz, 1H), 2.18–0.68 (m, 30 H), 0.52 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.0, 139.5, 131.5, 129.1, 127.1, 126.1, 116.7, 114.3, 72.3, 71.1, 66.1, 64.1, 56.5, 56.3, 54.5, 45.9, 44.4, 43.3, 40.4, 36.4, 36.1, 29.4, 29.3, 29.2, 27.6, 23.4, 22.2, 20.8, 18.8, 12.1; HRMS: calcd. for C₄₁H₅₇NO₃Na, 634.4236; found, 634.4231.

2 α -N-Acetyl-1 α -25(OH)₂ vitamin D₃ (III a). $[\alpha]_D^{26} = +62.8$ (c 0.6, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 6.46 (d, $J = 11.4$ Hz, 1H), 6.28 (d, $J = 8.3$ Hz, 1H), 5.93 (d, $J = 11.5$ Hz, 1H), 5.35 (d, $J = 1.8$ Hz, 1H), 5.09 (d, $J = 1.9$ Hz, 1H), 4.31 (d, $J = 3.3$ Hz, 1H), 4.03–3.96 (m, 1H), 3.89 (ddd, $J = 9.7, 9.7, 4.6$ Hz, 1H), 2.83 (d, $J = 12.8$ Hz, 1H), 2.70 (dd, $J = 13.7, 4.6$ Hz, 1H), 2.34–2.25 (m, 1H), 2.08 (s, 3H), 2.08–0.80 (m, 30H), 0.53 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.2, 144.5, 144.0, 130.7, 126.1, 117.0, 116.6, 74.7, 71.1, 70.6, 58.1, 56.4, 56.3, 45.9, 44.3, 43.4, 40.4, 36.4, 36.1, 29.5, 29.4, 29.2, 27.6, 23.5, 23.4, 22.2, 20.8, 18.8, 12.1; HRMS: calcd for C₂₉H₄₇NO₄Na, 496.3403; found, 496.3399.

2 α -N-Pivaloyl-1 α -25(OH)₂ vitamin D₃ (IIIb). [α]_D²³ = +37.5 (c 1.8, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 6.48–6.37 (m, 2H), 5.94 (d, *J* = 11.4 Hz, 1H), 5.35 (s, 1H), 5.08 (s, 1H), 4.33 (d, *J* = 3.2 Hz, 1H), 4.05–3.93 (m, 1H), 3.93–3.84 (m, 1H), 2.82 (d, *J* = 12.3 Hz, 1H), 2.65 (dd, *J* = 13.5, 4.4 Hz, 1H), 2.30 (t, *J* = 11.4 Hz, 1H), 2.05–0.80 (m, 39H), 0.52 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 180.8, 144.2, 132.1, 128.5, 125.8, 116.7, 116.4, 74.2, 71.1, 70.8, 57.8, 56.4, 56.3, 45.9, 44.3, 43.2, 40.4, 38.9, 36.3, 36.1, 29.5, 29.3, 29.2, 27.7, 27.6, 23.5, 22.2, 20.8, 18.8, 12.0; HRMS: calcd for C₃₂H₅₃NO₄Na, 538.3872; found, 538.3834.

2 α -N-Benzoyl-1 α -25(OH)₂ vitamin D₃ (IIIc). [α]_D²³ = +26.2 (c 1.3, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 7.89–7.31 (m, 5H), 6.98 (d, *J* = 8.0 Hz, 1H), 6.46 (d, *J* = 11.4 Hz, 1H), 5.97 (d, *J* = 11.4 Hz, 1H), 5.38 (s, 1H), 5.12 (s, 1H), 4.45 (d, *J* = 3.4 Hz, 1H), 4.25–4.17 (m, 1H), 4.09–4.00 (m, 1H), 2.83 (t, *J* = 13.1 Hz, 1H), 2.71 (dd, *J* = 13.8, 4.6 Hz, 1H), 2.36 (t, *J* = 11.8 Hz, 1H), 2.23–0.80 (m, 30H), 0.53 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.1, 144.1, 132.5, 132.0, 131.8, 131.0, 128.5, 127.2, 125.8, 116.8, 74.3, 71.1, 70.4, 58.5, 56.4, 56.3, 45.9, 44.3, 43.2, 40.4, 36.3, 36.1, 29.4, 29.3, 29.1, 27.6, 23.5, 22.2, 20.8, 18.8, 12.1; HRMS: calcd for C₃₄H₄₉NO₄Na, 558.3559; found, 558.3540.

2 α -N-tert-Butoxycarbonyl-1 α -25(OH)₂ vitamin D₃ (IVd). [α]_D³¹ = +44.7 (c 0.8, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 6.44 (d, *J* = 11.0 Hz, 1H), 5.94 (d, *J* = 11.0 Hz, 1H), 5.35 (s, 1H), 5.07 (s, 1H), 4.35 (d, *J* = 2.7 Hz, 1H), 3.92–3.84 (m, 1H), 3.73–3.64 (m, 1H), 2.82 (d, *J* = 12.8 Hz, 1H), 2.67 (dd, *J* = 13.5, 4.8 Hz, 1H), 2.27 (t, *J* = 11.5 Hz, 1H), 2.06–0.72 (m, 30H), 1.46 (s, 9H), 0.52 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 157.2, 144.3, 144.1, 131.1, 128.0, 125.8, 116.7, 80.4, 74.7, 71.1, 70.5, 59.1, 56.4, 56.3, 45.9, 44.3, 43.2, 40.4, 36.3, 36.1, 29.7, 29.3, 29.2, 28.3, 27.6, 23.4, 22.2, 20.8, 18.8, 12.1; HRMS: calcd for C₃₂H₅₃NO₅Na, 554.3821; found, 554.3814.

2 α -N-Methanesulfonyl-1 α -25(OH)₂ vitamin D₃ (Va). [α]_D¹⁴ = +29.4 (c 0.5, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 6.45 (d, *J* = 11.5 Hz, 1H), 5.93 (d, *J* = 11.4 Hz, 1H), 5.39 (s, 1H), 5.12 (s, 1H), 5.01 (d, *J* = 8.3 Hz, 1H), 4.47 (s, 1H), 4.00–3.87 (m, 1H), 3.51–3.38 (m, 1H), 3.01 (s, 3H), 2.82 (d, *J* = 11.9 Hz, 1H), 2.70 (dd, *J* = 13.5, 4.3 Hz, 1H), 2.35–2.20 (m, 1H), 2.10–0.75 (m, 30H), 0.53 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.6, 143.9, 130.3, 126.0, 116.9, 116.5, 74.2, 71.1, 69.3, 61.9, 56.5, 56.3, 46.0, 44.4, 42.1, 41.4, 40.4, 36.3, 36.1, 29.7, 29.4, 29.3, 27.6, 23.5, 22.2, 20.8, 18.8, 12.1; HRMS: calcd for C₂₈H₄₇NO₅Na, 532.3073; found, 532.3076.

2 α -N-Benzenesulfonyl-1 α -25(OH)₂ vitamin D₃ (Vb). [α]_D¹⁷ = +29.2 (c 0.8, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, *J* = 7.8 Hz, 1H), 7.62 (t, *J* = 7.4 Hz, 1H), 7.55 (t, *J* = 7.6 Hz, 2H), 6.42 (d, *J* = 11.4 Hz, 1H), 5.87 (d, *J* = 11.5 Hz, 1H), 5.31 (d, *J* = 8.3 Hz, 1H), 5.15 (s, 1H), 5.02 (d, *J* = 1.3 Hz, 1H), 3.94 (s, 1H), 3.91–3.81 (m, 1H), 3.23 (ddd, *J* = 8.7, 8.7, 3.2 Hz, 1H), 2.79 (d, *J* = 12.8 Hz, 1H), 2.67 (dd, *J* = 13.6, 4.9 Hz, 1H), 2.32 (s, 1H), 2.20 (t, *J* = 11.7 Hz, 1H), 2.05–0.82 (m, 30H), 0.50 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.6, 143.7, 140.3, 133.0, 130.2, 129.3, 127.1, 126.1, 116.9, 116.5, 73.4, 71.1, 68.7, 62.0,

56.4, 56.3, 45.9, 44.3, 41.6, 40.4, 36.3, 36.0, 29.3, 29.2, 29.1, 27.6, 23.4, 22.1, 20.8, 18.8, 12.1; HRMS: calcd for C₃₃H₄₉NO₅Na, 594.3229; found, 594.3271.

2 α -N-(4-tert-Butyl)-benzenesulfonyl-1 α -25(OH)₂ vitamin D₃ (Vc). [α]_D¹⁸ = +12.0 (c 0.4, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.85 (d, *J* = 8.6 Hz, 2H), 7.55 (t, *J* = 8.6 Hz, 2H), 6.42 (d, *J* = 11.5 Hz, 1H), 5.87 (d, *J* = 10.9 Hz, 1H), 5.24 (d, *J* = 8.6 Hz, 1H), 5.11 (d, *J* = 1.7 Hz, 1H), 5.01 (d, *J* = 1.7 Hz, 1H), 3.90 (d, *J* = 3.5 Hz, 1H), 3.86 (ddd, *J* = 13.7, 9.1, 4.6 Hz, 1H), 3.22 (dt, *J* = 8.6, 3.4 Hz, 1H), 2.79 (d, *J* = 12.6 Hz, 1H), 2.68 (dd, *J* = 13.8, 4.6 Hz, 1H), 2.21 (t, *J* = 11.8 Hz, 1H), 2.10–0.60 (m, 39H), 0.50 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 156.9, 144.6, 143.8, 137.1, 130.2, 127.0, 126.3, 126.2, 116.8, 116.5, 73.4, 71.1, 68.7, 61.9, 56.4, 56.3, 45.9, 44.4, 41.6, 40.4, 36.3, 36.1, 31.6, 31.1, 29.4, 29.2, 29.1, 27.6, 23.5, 22.1, 20.8, 18.8, 12.0; HRMS: calcd for C₃₇H₅₇NO₅Na, 650.3855; found, 650.3858.

2 α -N-(4-Methoxy)-benzenesulfonyl-1 α -25(OH)₂ vitamin D₃ (Vd). [α]_D²⁰ = +12.2 (c 0.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.86 (d, *J* = 9.1 Hz, 2H), 7.00 (d, *J* = 8.6 Hz, 2H), 6.42 (d, *J* = 11.5 Hz, 1H), 5.87 (d, *J* = 11.5 Hz, 1H), 5.22 (d, *J* = 8.6 Hz, 1H), 5.18 (s, 1H), 5.03 (d, *J* = 1.1 Hz, 1H), 3.99 (d, *J* = 3.5 Hz, 1H), 3.88 (s, 3H), 3.88–3.81 (m, 1H), 3.19 (dt, *J* = 8.6, 3.5 Hz, 1H), 2.79 (d, *J* = 13.2 Hz, 1H), 2.67 (dd, *J* = 13.2, 4.6 Hz, 1H), 2.20 (t, *J* = 11.8 Hz, 1H), 2.10–0.60 (m, 39H), 0.50 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 163.1, 144.6, 143.8, 131.7, 130.3, 129.3, 126.1, 116.9, 116.5, 114.4, 73.4, 71.1, 68.7, 61.9, 56.4, 56.3, 55.6, 45.9, 44.3, 41.6, 40.4, 36.3, 36.0, 29.3, 29.2, 29.1, 27.6, 23.5, 22.1, 20.8, 18.8, 12.0; HRMS: calcd for C₃₄H₅₁NO₆Na, 624.3335; found, 624.3337.

2 β -N,N'-Dibenzyl-1 α -25(OH)₂ vitamin D₃ (VIIe). To a solution of **5** (40 mg, 0.0346 mmol) and **32** (42 mg, 0.0737 mmol) in toluene and triethylamine (1 : 1, 2 mL) was added Pd(PPh₃)₄ (about 50 mg) at room temperature. The resulting mixture was stirred at room temperature for 15 min, then 100 °C for 3 h. The resulting mixture was cooled to room temperature, and diluted with ethyl acetate, filtered through a pad of Celite, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (hexane–ethyl acetate = 20 : 1) to give bis silylether. To a solution of bis silylether in THF (1.0 mL) was added HF–Et₃N (1.0 mL), and the mixture was stirred for 15 h. To the reaction mixture was added saturated NaHCO₃, and the mixture was stirred for 30 min. The resulting mixture was extracted with ethyl acetate, and the organic layer was washed with brine. The extracts were dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel chromatography (CHCl₃–MeOH = 9 : 1) to give **VIIe** (8.7 mg, 0.0142 mmol, 21%). [α]_D¹⁸ = –35.3 (c 0.1, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.33–7.24 (m, 10H), 6.34 (d, *J* = 10.8 Hz, 1H), 6.08 (d, *J* = 10.8 Hz, 1H), 5.46 (s, 1H), 4.94 (s, 1H), 4.52 (s, 1H), 4.44 (d, *J* = 10.8 Hz, 1H), 4.16 (d, *J* = 13.7 Hz, 2H), 3.66 (d, *J* = 13.7 Hz, 2H), 2.80 (dd, *J* = 3.4, 12.6 Hz, 1H), 2.56 (d, *J* = 10.8 Hz, 1H), 2.38–0.83 (m, 26H), 0.93 (d, *J* = 5.7 Hz, 3H), 0.53 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 143.7, 139.4, 131.7, 131.0, 128.8, 128.5, 127.1, 126.2, 116.9, 110.4, 71.0, 66.6, 66.0, 65.8, 56.4, 56.3, 54.2, 50.9, 45.9, 44.3, 40.3, 36.3,

36.0, 31.9, 29.6, 29.3, 29.2, 27.6, 23.7, 22.2, 20.7, 18.8, 11.8; HRMS: (ESI, M + H⁺) calcd for C₄₁H₅₈NO₃, 612.4416; found, 612.4422.

2 β -N-Substituted vitamin D derivatives VIIIa and Xa. As described for VIIe, VIIIa and Xa were obtained from the corresponding A-ring synthons (33 and 34), respectively.

2 β -N-Acetyl-1 α -25(OH)₂ vitamin D₃ (VIIIa). [α]_D²⁰ = -15.6 (c 0.3, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 6.39–6.33 (m, 2H), 6.03 (d, *J* = 11.4 Hz, 1H), 5.59 (s, 1H), 5.09 (s, 1H), 4.13–4.04 (m, 2H), 3.96–3.89 (m, 1H), 2.80 (d, *J* = 10.8 Hz, 1H), 2.61 (d, *J* = 13.1 Hz, 1H), 2.15 (d, *J* = 14.3 Hz, 1H), 2.08 (s, 3H), 2.20–0.84 (m, 24H), 0.93 (d, *J* = 5.1 Hz, 3H), 0.54 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.4, 145.1, 144.1, 131.0, 125.9, 116.7, 112.2, 73.7, 71.0, 69.4, 58.4, 56.5, 56.3, 46.0, 44.3, 42.4, 40.3, 36.3, 36.0, 29.6, 29.3, 29.2, 27.5, 23.7, 23.3, 22.1, 20.7, 18.8, 11.8; HRMS: (ESI, M + Na⁺) calcd for C₂₉H₄₇NO₄Na, 496.3402; found, 496.3405.

2 β -N-Methanesulfonyl-1 α -25(OH)₂ vitamin D₃ (Xa). [α]_D²¹ = -41.4 (c 0.3, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 6.35 (d, *J* = 10.9 Hz, 1H), 6.00 (d, *J* = 11.4 Hz, 1H), 5.52 (s, 1H), 5.24 (d, *J* = 8.24 Hz, 1H), 5.12 (s, 1H), 4.23–4.14 (m, 2H), 3.39–3.32 (m, 1H), 3.09 (s, 3H), 2.80 (d, *J* = 10.9 Hz, 1H), 2.57 (d, *J* = 14.6 Hz, 1H), 2.44 (d, *J* = 14.2 Hz, 1H), 2.09–0.84 (m, 24H), 0.93 (d, *J* = 5.9 Hz, 3H), 0.54 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.5, 144.1, 130.9, 125.7, 116.6, 112.3, 71.6, 71.1, 69.8, 62.6, 56.5, 56.3, 46.0, 44.3, 42.0, 41.4, 40.3, 36.3, 36.0, 29.6, 29.3, 29.2, 27.5, 23.7, 22.3, 20.7, 18.8, 11.8; HRMS: (ESI, M + Na⁺) calcd for C₂₈H₄₇NO₅SNa, 532.3072; found, 532.3089.


Acknowledgements

This study was supported in part by the Advanced research for medical products Mining Programme of the National Institute of Biomedical Innovation (NIBIO) and Grant-in Aid for Scientific Research on Innovative Areas.

Notes and references


- (a) S. A. Kliewer, K. Umeson, D. J. Mangelsdorf and R. M. Evans, *Nature*, 1992, **355**, 446; (b) D. J. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umeson, B. Blumberg, P. Kastner, M. Mark, P. Chambon and R. M. Evans, *Cell*, 1995, **83**, 835; (c) S. Björklund, G. Almouzni, I. Davidson and K. P. Nightingale, *Cell*, 1999, **96**, 759; (d) K. Takeyama, Y. Masuhiro, H. Fuse, H. Endoh, A. Murayama, S. Kitanaka, M. Suzuwa, J. Yanagisawa and S. Kato, *Mol. Cell. Biol.*, 1999, **19**, 1049; (e) M. R. Haussler, C. A. Haussler, L. Bartik, G. K. Whitfield, J.-C. Hsieh, S. Slater and P. W. Jurutka, *Nutr. Rev.*, 2008, **66**, s98; (f) R. Bouillon, G. Carmeliet, L. Verlinden, E. V. Etten, A. Verstuyf, H. F. Luderer, L. Lieben, C. Mathieu and M. Demay, *Endocrine Rev.*, 2008, **29**, 726.
- (a) T. Suda, T. Shinki and N. Takahashi, *Annu. Rev. Nutr.*, 1990, **10**, 195; (b) R. Bouillon, W. H. Okamura and A. W. Norman, *Endocrine Rev.*, 1995, **16**, 200; (c) H. F. DeLuca, *Am. J. Clin. Nutr.*, 2004, **80**, 1689S.
- (a) E. Abe, C. Miyaura, H. Sakagami, M. Takeda, K. Konno, T. Yamazaki, S. Yoshiki and T. Suda, *Proc. Natl. Acad. Sci. U. S. A.*, 1981, **78**, 4990; (b) X. Wang and G. P. Studzinski, *J. Steroid Biochem. Mol. Biol.*, 2010, **97**, 395.
- (a) M. W. Tilyard, G. F. S. Spears, J. Thomson and S. Dovey, *N. Engl. J. Med.*, 1992, **326**, 357; (b) M. F. Holick, *Am. J. Clin. Nutr.*, 2004, **79**, 362; (c) E. A. Slatopolsky, C. Weerts, J. Thielan, R. Horst, H. Harter and K. J. Marti, *J. Clin. Invest.*, 1984, **74**, 2136; (d) K. E. Lowe and A. W. Norman, *Nutr. Rev.*, 1992, **50**, 138.
- (a) S. Ishizuka, K. Bannai, T. Naruuchi, Y. Hashimoto, T. Noguchi and N. Hosoya, *J. Biochem.*, 1980, **88**, 87; (b) E. Slatopolsky, J. Finch, C. Ritter, M. Denda, J. Morrissey, A. Brown and H. DeLuca, *Am. J. Kidney Dis.*, 1995, **26**, 852; (c) N. Saito, Y. Suhara, M. Kurihara, T. Fujishima, S. Honzawa, H. Takayanagi, T. Kozono, M. Matsumoto, M. Ohmori, N. Miyata, H. Takayama and A. Kittaka, *J. Org. Chem.*, 2004, **69**, 7463; (d) N. Kubodera, *Curr. Bioact. Compd.*, 2006, **2**, 301; (e) N. Kubodera, *Heterocycles*, 2010, **80**, 83.
- M. Shimizu, Y. Miyamoto, H. Takaku, M. Matsuo, M. Nakabayashi, H. Masuno, N. Udagawa, H. F. DeLuca, T. Ikura and N. Ito, *Bioorg. Med. Chem.*, 2008, **16**, 6949.
- A. Kittaka, Y. Suhara, H. Takayanagi, T. Fujishima, M. Kurihara and H. Takayama, *Org. Lett.*, 2000, **2**, 2619.
- (a) Y. Suhara, K. Nihei, H. Tanigawa, T. Fujishima, K. Konno, K. Nakagawa, T. Okano and H. Takayama, *Bioorg. Med. Chem. Lett.*, 2000, **10**, 1129; (b) Y. Suhara, K. Nihei, M. Kurihara, A. Kittaka, K. Yamaguchi, T. Fujishima, K. Konno, N. Miyata and H. Takayama, *J. Org. Chem.*, 2001, **66**, 8760; (c) S. Honzawa, Y. Suhara, K. Nihei, N. Saito, S. Kishimoto, T. Fujishima, M. Kurihara, T. Sugiura, K. Waku, H. Takayama and A. Kittaka, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 3503.
- (a) K. Konno, S. Maki, T. Fujishima, Z. P. Liu, D. Miura, M. Chokki and H. Takayama, *Bioorg. Med. Chem. Lett.*, 1998, **8**, 151; (b) K. Konno, T. Fujishima, S. Maki, Z. P. Liu, D. Miura, M. Chokki, S. Ishizuka, K. Yamaguchi, Y. Kan, M. Kurihara, N. Miyata, C. Smith, H. F. DeLuca and H. Takayama, *J. Med. Chem.*, 2000, **43**, 4247.
- N. Rochel, J. M. Wurtz, A. Mitschler, B. B. Klaholz and D. Moras, *Mol. Cell*, 2000, **5**, 173.
- (a) K. Miyamoto, E. Murayama, K. Ochi, H. Watanabe and N. Kubodera, *Biol. Pharm. Bull.*, 1993, **43**, 1111; (b) N. Tsugawa, K. Nakagawa, M. Kurobe, Y. Ono, N. Kubodera, K. Ozono and T. Okano, *Biol. Pharm. Bull.*, 2000, **23**, 66; (c) N. Kubodera and S. Hatakeyama, *Heterocycles*, 2009, **79**, 145.
- (a) R. R. Scinski, J. M. Prah, C. M. Smith and H. F. DeLuca, *J. Med. Chem.*, 1998, **41**, 4662; (b) H. Yamamoto, N. K. Shevde, A. Warrior, L. A. Plum and H. F. DeLuca, *J. Biol. Chem.*, 2003, **278**, 31756; (c) H. F. DeLuca, *J. Steroid Biochem. Mol. Biol.*, 2004, **89–90**, 67; (d) H. Z. Ke, H. Qi, D. T. Crawford, H. A. Simmons, G. Xu, M. Li, L. Plum, M. Clagett-Dame, H. F. DeLuca, D. D. Thompson and T. A. Brown, *J. Bone Miner. Res.*, 2005, **20**, 1742.
- (a) Y. Kato, Y. Hashimoto and K. Nagasawa, *Molecules*, 2003, **8**, 488; (b) Y. Kato, Y. Nakano, H. Sano, A. Tanatani, H. Kobayashi, R. Shimazawa, H. Koshino, H. Hashimoto and K. Nagasawa, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 2579; (c) Y. Nakano, Y. Kato, K. Imai, E. Ochiai, J. Namekawa, S. Ishizuka, K. Takenouchi, A. Tanatani, Y. Hashimoto and K. Nagasawa, *J. Med. Chem.*, 2006, **49**, 2398; (d) K. Cho, F. Uneuchi, Y. Kato-Nakamura, J. Namekawa, S. Ishizuka, K. Takenouchi and K. Nagasawa, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 4278.
- R. A. Friesner, J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. Mainz, M. P. Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw, P. Francis and P. S. Shenkin, *J. Med. Chem.*, 2004, **47**, 1739.
- Vitamin D₃ derivatives were docked into the X-ray structure of VDR (PDB code: 1DB1) using Glide 5.0 (Schrödinger, LLC). Hydrogen-bonding interaction between compounds and VDR and their visualization were generated by PyMOL (Schrödinger, LLC).
- Lower values of docking score indicate more favorable interaction with VDR.
- B. M. Trost, J. Dumas and M. Villa, *J. Am. Chem. Soc.*, 1992, **114**, 9836.
- T. Yamamoto, H. Hasegawa, T. Hakogi and S. Katsumura, *Org. Lett.*, 2006, **8**, 5569.
- The diastereomer ratio of the alcohol was determined by ¹H NMR.
- G. Ageno, L. Banfi, G. Cascio, G. Guanti, E. Manghisi, R. Riva and V. Rocca, *Tetrahedron*, 1995, **51**, 8121.
- (a) W. J. Gensler, F. Johnson and A. D. B. Sloan, *J. Am. Chem. Soc.*, 1960, **82**, 6074; (b) H. H. Wasserman, M. Xia, J. Wang, A. K. Petersen and M. Jorgensen, *Tetrahedron Lett.*, 1999, **40**, 6163; (c) H. H. Wasserman, A. K. Peterson and M. Xia, *Tetrahedron*, 2003, **59**, 6771.
- Synthesis of epoxide **28** via Corey–Chaikevsky reaction with Garner aldehyde has been reported.²³ We examined the reported procedure, but found that epimerization at C-2 took place under the reaction conditions, affording **28** and **36** as a 1:1 mixture. [α]_D²⁰ = +1.18 (c 1.2, CHCl₃); reported [α]_D²⁰ = +1.46 (c 1, CHCl₃). The method employed here

(Scheme 3) afforded **28** as a sole product. $[\alpha]_D^{22} = +12.5$ (*c* 1.1, CHCl_3).



- 23 (a) W. J. Moore and F. A. Luzzio, *Tetrahedron Lett.*, 1995, **36**, 6599;
 (b) C. Bedia, J. Casas, V. Garcia, T. Levade and G. Fabrias, *ChemBioChem*, 2007, **8**, 642.
 24 X. Cong, F. Fu, K.-G. Liu, Q.-J. Liao and Z.-J. Yao, *J. Org. Chem.*, 2005, **70**, 4514.

25 Unfortunately coupling reaction with **5** did not take place in the case of *N*-monoalkyl A-ring synthons, and we could not obtain 2-*N*-monoalkyl 1,25-VD₃ derivatives **I** and **VI**.



- 26 F. Jehan and H. F. Deluca, *Proc. Natl. Acad. Sci. U. S. A.*, 1997, **94**, 10138.